Physician profile
Nicole E Berge
NPI 1457329575
$9,551.47
in general payments reported to CMS, 2019-2025
40 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,408 · 2022: $2,296 · 2023: $2,638 · 2024: $1,842 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,848.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,847.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,523.42 | 2021-2025 | Rybelsus, Ozempic, Norditropin |
| Lilly USA, LLC | $1,251.52 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $878.22 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.05 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $643.97 | 2021-2025 | |
| Amgen INC. | $398.03 | 2021-2025 | Evenity, Prolia, Tepezza |
| Dexcom, INC. | $378.40 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $338.47 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $306.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $286.94 | 2021-2022 | |
| Mannkind Corporation | $282.08 | 2022-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $231.02 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $206.71 | 2023-2025 | |
| Radius Health, INC. | $194.43 | 2023-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $172.37 | 2023-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $162.55 | 2022-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $153.09 | 2022-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $146.43 | 2021-2023 | Steglujan, Steglatro |
| Ascendis Pharma Endocrinology INC | $137.16 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $115.94 | 2021 | |
| Cequr Corporation | $107.40 | 2023-2024 | Cequr Simplicity |
| Medtronic, INC. | $105.28 | 2021-2024 | Minimed 780g |
| Recordati_rare_diseases_inc. | $101.11 | 2023-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $93.39 | 2021-2025 | Licart, Tirosint, Tirosint |
| Pfizer INC. | $89.52 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $87.80 | 2023-2025 | Strensiq |
| Xeris Pharmaceuticals, INC. | $75.23 | 2023-2025 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $70.41 | 2025 | Twiist |
| Grt US Holding, INC. | $67.05 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $57.58 | 2021-2022 | |
| Antares Pharma, INC. | $41.60 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Insulet Corporation | $38.13 | 2022-2023 | Omnipod |
| Boston Scientific Corporation | $35.20 | 2024 | Wavewriter Alpha Prime 16 |
| Esperion Therapeutics, INC. | $28.33 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.40 | 2023 | |
| Beta Bionics, INC. | $20.00 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Zealand Pharma US, INC. | $15.11 | 2021 | |
| Amryt Pharma Holdings Ltd | $14.47 | 2021 | |
| Halozyme INC | $13.79 | 2023 | |
| Vistapharm, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Berge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.